The only specific treatment available for emphysema associated with AATD is the intravenous infusion of AAT purified from human plasma donors; i.e., augmentation therapy, which raises serum AAT levels above the theoretically protective threshold level of 11 μM/L, delaying the progression of emphysema [13,14]. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.